Oral administration of a dual analog of two myasthenogenic T cell epitopes down-regulates experimental autoimmune myasthenia gravis in mice

Documenti analoghi

• A peptide composed of tandem analogs of two myasthenogenic T cell epitopes interferes with specific autoimmune responses
  di: Katz-Levy, Yael, et al.
  Pubblicazione: (1997)
• The nature of the active suppression of responses associated with experimental autoimmune myasthenia gravis by a dual altered peptide ligand administered by different routes
  di: Paas-Rozner, Miri, et al.
  Pubblicazione: (2001)
• A dual altered peptide ligand down-regulates myasthenogenic T cell responses by up-regulating CD25- and CTLA-4-expressing CD4(+) T cells
  di: Paas-Rozner, Miri, et al.
  Pubblicazione: (2003)
• Altered peptide ligands act as partial agonists by inhibiting phospholipase C activity induced by myasthenogenic T cell epitopes
  di: Faber-Elmann, Anat, et al.
  Pubblicazione: (1998)
• Peptide analogs to pathogenic epitopes of the human acetylcholine receptor alpha subunit as potential modulators of myasthenia gravis.
  di: Zisman, E, et al.
  Pubblicazione: (1996)